Open AccessThe expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer
Author(s) -
Siyuan Cheng,
Néstor Prieto-Domínguez,
Shu Yang,
Zachary M. Connelly,
Samantha StPierre,
Bryce Rushing,
Andy Watkins,
Lawrence Shi,
Meredith A. Lakey,
Lyndsey Buckner Baiamonte,
Tajammul Fazili,
A. Lurie,
Eva Corey,
Runhua Shi,
Yunshin Yeh,
Xiuping Yu
Publication year - 2020
Publication title -
prostate cancer and prostatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2
H-Index - 64
eISSN - 1476-5608
pISSN - 1365-7852
DOI - 10.1038/s41391-020-0229-z
Subject(s) - yap1 , prostate cancer , medicine , prostate , immunohistochemistry , cancer research , neuroendocrine differentiation , adenocarcinoma , cancer , pathology , oncology , biology , transcription factor , gene , biochemistry
After long-term androgen deprivation therapy, 25-30% prostate cancer (PCa) acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of YAP1, a key transcription coactivator of the Hippo pathway, has been related to cancer progression. However, its role in neuroendocrine prostate cancer (NEPC) has not been assessed.